Successful treatment of Aspergillus liver abscesses in a patient with acute monoblastic leukemia using combination antifungal therapy including micafungin as a key drug

International Journal of Hematology

Volumn 91, Issue 4, 2010, Pages 711-715

  Yamada, Rie ^a   Horikawa, Kentaro ^a   Ishihara, Sonoko ^b   Hoshino, Koyu ^a   Kawaguchi, Tatsuya ^a   Iyama, Ken Ichi ^b   Mitsuya, Hiroaki ^a   Asou, Norio ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Antifungal therapy; Aspergillosis; Leukemia; Liver abscess; Micafungin

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIINFECTIVE AGENT; BETA GLUCAN; CYTARABINE; FLUCONAZOLE; ITRACONAZOLE; METHYLPREDNISOLONE; MICAFUNGIN; VORICONAZOLE;

ACUTE MONOCYTIC LEUKEMIA; ADD ON THERAPY; ADULT; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; BLOOD ANALYSIS; CANCER CHEMOTHERAPY; CASE REPORT; DEATH; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MEGADOSE; DRUG SUBSTITUTION; FEBRILE NEUTROPENIA; HUMAN; INTENSIVE CARE; INTERSTITIAL PNEUMONIA; INVASIVE ASPERGILLOSIS; LIVER ABSCESS; LIVER BIOPSY; MALE; MONOTHERAPY; MYCOSIS; NEUTROPENIA; SERUM; THORAX RADIOGRAPHY; TISSUE; TREATMENT RESPONSE;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; DRUG THERAPY, COMBINATION; ECHINOCANDINS; HEPATITIS; HUMANS; LEUKEMIA, MONOCYTIC, ACUTE; LIPOPEPTIDES; LIVER ABSCESS; MALE; MIDDLE AGED;

EID: 77954538712     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0556-2     Document Type: Article

References (30)

1. Maschmeyer G, Hiddemann W, Link H, Cornely OA, Buchheidt D, Glaß B, et al. Management of infections during intensive treatment of hematologic malignancies. Ann Hematol. 1997;75:9-16.
2. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91:1068-1075
3. Nosari A, Oreste P, Cairoli R, Montillo M, Carrafiello G, Astolfi A, et al. Invasive aspergillosis in haematological malignancies: clinical findings and management for intensive chemotherapy completion. Am J Hematol. 2001;68:231-236
4. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis. 2007;44:531-540
5. Holding KJ, Dworkin MS, Wan PCT, Hanson DL, Klevens RM, Jones JL, et al. Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. Clin Infect Dis. 2000;31:1253-1257
6. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327-360
7. Slain D, Rogers PD, Cleary JD, Chapman SW. Intravenous itraconazole. Ann Pharmacother. 2001;35:720-729
8. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36:630-637
9. Kartsonis NA, Nielsen J, Douglas CM. Caspofungin: the first in a new class of antifungal agents. Drug Resist Updat. 2003;6:197-218.
10. Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006;53:337-349
11. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med. 1999;340:764-771 (Pubitemid 29114295)
12. Kawazu M, Kanda Y, Nannya Y, Aoki K, Kurokawa M, Chiba S, et al. Prospective comparison of the diagnostic potential of realtime PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1 ? 3)-b-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol. 2004;42:2733-2741
13. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14.
14. Pagano L, Girmenia C, Mele L, Ricci P, Tosti ME, Nosari A, et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica. 2001;86:862-870
15. Potenza L, Barozzi P, Rossi G, Palazzi G, Vallerini D, Riva G, et al. Assessment of Aspergillus-specific T cells for diagnosis of invasive aspergillosis in a leukemic child with liver lesions mimicking hepatosplenic candidiasis. Clin Vaccine Immunol. 2008;15:1625-1628
16. Hwang YKW, Joo NH, Tee GY, Tan P, Tan L, Girija R. Clinical activity of the new triazole drug voriconazole (UK 109, 496) against disseminated hepatosplenic aspergillosis in a patient with relapsed leukemia. Haematologica. 2001;31:73-80.
17. Shouldice E, Fernandez C, McCully B, Schmidt M, Fraser R, Cook C. Voriconazole treatment of presumptive disseminated Aspergillus infection in a child with acute leukemia. J Pediatr Hematol Oncol. 2003;25:732-734
18. Gercovich FG, Richman SP, Rodriguez V, Luna M, McCredie KB, Bodey GP. Successful control of systemic Aspergillus niger infections in two patients with acute leukemia. Cancer. 1975;36:2271-2276
19. Gowing NFC, Hamlin IME. Tissue reactions to Aspergillus in cases of Hodgkin's disease and leukemia. J Clin Pathol. 1960;13:396-413.
20. Gottfredsson M, Steingrimsdottir H. Disseminated invasive aspergillosis in a patient with acute leukemia. Acta Biomed. 2006;77(Suppl 2):10-13
21. Senn L, Robinson JO, Schmidt S, Knaup M, Asahi N, Satomura S, et al. 1,3-b-D-Glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis. 2008;46:878-885
22. Ashley ESD, Lewis R, Lewis JS, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis. 2006;43:S28-39.
23. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004;39:797-802.
24. Caillot D, Thiébaut A, Herbrecht R, de Botton S, Pigneux A, Bernard F, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer. 2007;110:2740-2746
25. Aliff TB, Maslak PG, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer. 2003;97:1025-1032
26. Meletiadis J, Petraitis V, Petraitiene R, Lin P, Stergiopoulou T, Kelaher AM, et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis. 2006;194:1008-1018
27. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45:649-663
28. Herbert MF, Smith HE, Marbury TG, Swan SK, Smith WB, Townsend RW, et al. Pharmacokinetics of micagungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol. 2005;45:1145-1152
29. Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362:1142-1151
30. van der Velden WJFM, Blijlevens NMA, Klont RR, Donnelly JP, Verweij PE. Primary hepatic invasive aspergillosis with progression after rituximab therapy for a post transplantation lymphoproliferative disorder. Ann Hematol. 2006;85:621-623